Adaptive Biotechnologies Corp (NASDAQ:ADPT) shares, rose in value, with the stock price up by 0.38% to the previous day’s close as strong demand from buyers drove the stock to $2.61.
Actively observing the price movement in the last trading, the stock closed the session at $2.60. Referring to stock’s 52-week performance, its high was $9.08, and the low was $2.28. On the whole, ADPT has fluctuated by -9.38% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 175.82M, with a low estimate of 34.8M and a high estimate of 42.2M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 38.78M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ADPT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ADPT currently trading nearly -4.68% and -20.72% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.84, while the 7-day volatility ratio is showing 7.94% which for the 30-day chart, stands at 9.14%. Furthermore, Adaptive Biotechnologies Corp (ADPT)’s beta value is 1.27, and its average true range (ATR) is 0.25.
A comparison of Adaptive Biotechnologies Corp (ADPT) with its peers suggests the former has fared considerably weaker in the market. ADPT showed an intraday change of 0.38% in last session, and over the past year, it shrunk by -64.92%%.
Data on historical trading for Adaptive Biotechnologies Corp (NASDAQ:ADPT) indicates that the trading volumes over the past 3 months, they’ve averaged 1.69 million. According to company’s latest data on outstanding shares, there are 145.08 million shares outstanding.
Nearly 4.54% of Adaptive Biotechnologies Corp’s shares belong to company insiders and institutional investors own 98.12% of the company’s shares. The stock has fallen by -46.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADPT stock heading into the next quarter.
